Advertisement
Screener

CARDIFF ONCOLOGY, INC. (CRDF) Comprehensive Income

2.0 / 5 stars · 44/111 Roast Me

CARDIFF ONCOLOGY, INC. Comprehensive Income

CARDIFF ONCOLOGY, INC. (CRDF) reported Comprehensive Income of -$9.24 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.

Financial Statements › Income Statement › Unrealized Gains

us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-11

  • CARDIFF ONCOLOGY, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$9.24M.
  • CARDIFF ONCOLOGY, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$12.44M.
  • CARDIFF ONCOLOGY, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$7.22M.
  • CARDIFF ONCOLOGY, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$11.22M.
  • CARDIFF ONCOLOGY, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$45.84M.
  • CARDIFF ONCOLOGY, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$45.33M.
  • CARDIFF ONCOLOGY, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$41.11M.
  • CARDIFF ONCOLOGY, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$38.96M.
Period endComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month
2026-06-30-$9.24M
10-Q · filed 2026-08-11
-$21.69M
10-Q · filed 2026-08-11
-$28.91M
derived: sum of 3 quarters · filed 2026-08-11
-$40.13M
derived: sum of 4 quarters · filed 2026-08-11
2026-03-31-$12.44M
10-Q · filed 2026-05-14
-$19.66M
derived: sum of 2 quarters · filed 2026-05-14
-$30.89M
derived: sum of 3 quarters · filed 2026-05-14
-$44.84M
derived: sum of 4 quarters · filed 2026-08-11
2025-12-31-$7.22M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
-$18.44M
derived: sum of 2 quarters · filed 2026-02-24
-$32.39M
derived: sum of 3 quarters · filed 2026-08-11
-$45.84M
10-K · filed 2026-02-24
2025-09-30-$11.22M
10-Q · filed 2025-11-06
-$25.18M
derived: sum of 2 quarters · filed 2026-08-11
-$38.62M
10-Q · filed 2025-11-06
-$50.45M
derived: sum of 4 quarters · filed 2026-08-11
2025-06-30-$13.95M
10-Q · filed 2026-08-11
-$27.39M
10-Q · filed 2026-08-11
-$39.23M
derived: sum of 3 quarters · filed 2026-08-11
-$50.91M
derived: sum of 4 quarters · filed 2026-08-11
2025-03-31-$13.44M
10-Q · filed 2026-05-14
-$25.28M
derived: sum of 2 quarters · filed 2026-05-14
-$36.95M
derived: sum of 3 quarters · filed 2026-05-14
-$48.70M
derived: sum of 4 quarters · filed 2026-05-14
2024-12-31-$11.84M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
-$23.51M
derived: sum of 2 quarters · filed 2026-02-24
-$35.25M
derived: sum of 3 quarters · filed 2026-02-24
-$45.33M
10-K · filed 2026-02-24
2024-09-30-$11.68M
10-Q · filed 2025-11-06
-$23.42M
derived: sum of 2 quarters · filed 2025-11-06
-$33.49M
10-Q · filed 2025-11-06
-$42.49M
derived: sum of 4 quarters · filed 2025-11-06
2024-06-30-$11.74M
10-Q · filed 2025-07-29
-$21.82M
10-Q · filed 2025-07-29
-$30.82M
derived: sum of 3 quarters · filed 2025-07-29
-$40.52M
derived: sum of 4 quarters · filed 2025-07-29
2024-03-31-$10.08M
10-Q · filed 2025-05-08
-$19.07M
derived: sum of 2 quarters · filed 2025-05-08
-$28.78M
derived: sum of 3 quarters · filed 2025-05-08
-$40.28M
derived: sum of 4 quarters · filed 2025-05-08
2023-12-31-$9.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
-$18.70M
derived: sum of 2 quarters · filed 2025-02-27
-$30.21M
derived: sum of 3 quarters · filed 2025-02-27
-$41.11M
10-K · filed 2025-02-27
2023-09-30-$9.71M
10-Q · filed 2024-11-07
-$21.21M
derived: sum of 2 quarters · filed 2024-11-07
-$32.12M
10-Q · filed 2024-11-07
-$40.43M
derived: sum of 4 quarters · filed 2024-11-07
2023-06-30-$11.51M
10-Q · filed 2024-08-08
-$22.41M
10-Q · filed 2024-08-08
-$30.72M
derived: sum of 3 quarters · filed 2024-08-08
-$39.09M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31-$10.90M
10-Q · filed 2024-05-02
-$19.22M
derived: sum of 2 quarters · filed 2024-05-02
-$27.59M
derived: sum of 3 quarters · filed 2024-05-02
-$38.26M
derived: sum of 4 quarters · filed 2024-05-02
2022-12-31-$8.31M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
-$16.68M
derived: sum of 2 quarters · filed 2024-02-29
-$27.36M
derived: sum of 3 quarters · filed 2024-02-29
-$38.96M
10-K · filed 2024-02-29
2022-09-30-$8.37M
10-Q · filed 2023-11-02
-$19.05M
derived: sum of 2 quarters · filed 2023-11-02
-$30.64M
10-Q · filed 2023-11-02
-$40.24M
derived: sum of 4 quarters · filed 2023-11-02
2022-06-30-$10.68M
10-Q · filed 2023-08-09
-$22.28M
10-Q · filed 2023-08-09
-$31.88M
derived: sum of 3 quarters · filed 2023-08-09
-$38.76M
derived: sum of 4 quarters · filed 2023-08-09
2022-03-31-$11.60M
10-Q · filed 2023-05-04
-$21.20M
derived: sum of 2 quarters · filed 2023-05-04
-$28.09M
derived: sum of 3 quarters · filed 2023-05-04
-$34.79M
derived: sum of 4 quarters · filed 2023-05-04
2021-12-31-$9.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02
-$16.49M
derived: sum of 2 quarters · filed 2023-03-02
-$23.19M
derived: sum of 3 quarters · filed 2023-03-02
-$28.43M
10-K · filed 2023-03-02
2021-09-30-$6.89M
10-Q · filed 2022-11-03
-$13.59M
derived: sum of 2 quarters · filed 2022-11-03
-$18.83M
10-Q · filed 2022-11-03
-$25.43M
derived: sum of 4 quarters · filed 2022-11-03
2021-06-30-$6.70M
10-Q · filed 2022-08-04
-$11.95M
10-Q · filed 2022-08-04
-$18.54M
derived: sum of 3 quarters · filed 2022-08-04
-$23.04M
derived: sum of 4 quarters · filed 2022-08-04
2021-03-31-$5.25M
10-Q · filed 2022-05-05
-$11.84M
derived: sum of 2 quarters · filed 2022-05-05
-$16.34M
derived: sum of 3 quarters · filed 2022-05-05
-$20.46M
derived: sum of 4 quarters · filed 2022-05-05
2020-12-31-$6.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24
-$11.09M
derived: sum of 2 quarters · filed 2022-02-24
-$15.22M
derived: sum of 3 quarters · filed 2022-02-24
-$19.31M
10-K · filed 2022-02-24
2020-09-30-$4.50M
10-Q · filed 2021-11-04
-$8.62M
derived: sum of 2 quarters · filed 2021-11-04
-$12.71M
10-Q · filed 2021-11-04
2020-06-30-$4.12M
10-Q · filed 2021-08-05
-$8.21M
10-Q · filed 2021-08-05
2020-03-31-$4.09M
10-Q · filed 2021-05-06
2018-12-31-$6.95M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06
-$10.72M
derived: sum of 2 quarters · filed 2019-03-06
-$14.47M
derived: sum of 3 quarters · filed 2019-03-06
-$19.25M
10-K · filed 2019-03-06
2018-09-30-$3.77M
10-Q · filed 2018-11-07
-$7.52M
derived: sum of 2 quarters · filed 2018-11-07
-$12.30M
10-Q · filed 2018-11-07
-$14.88M
derived: sum of 4 quarters · filed 2019-03-06
2018-06-30-$3.75M
10-Q · filed 2018-08-03
-$8.53M
10-Q · filed 2018-08-03
-$11.11M
derived: sum of 3 quarters · filed 2019-03-06
-$15.41M
derived: sum of 4 quarters · filed 2019-03-06
2018-03-31-$4.79M
10-Q · filed 2018-05-08
-$7.36M
derived: sum of 2 quarters · filed 2019-03-06
-$11.66M
derived: sum of 3 quarters · filed 2019-03-06
-$19.70M
derived: sum of 4 quarters · filed 2019-03-06
2017-12-31-$2.58M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06
-$6.87M
derived: sum of 2 quarters · filed 2019-03-06
-$14.92M
derived: sum of 3 quarters · filed 2019-03-06
-$24.92M
10-K · filed 2019-03-06
2017-09-30-$4.29M
10-Q · filed 2018-11-07
-$12.34M
derived: sum of 2 quarters · filed 2018-11-07
-$22.34M
10-Q · filed 2018-11-07
-$61.58M
derived: sum of 4 quarters · filed 2018-11-07
2017-06-30-$8.05M
10-Q · filed 2018-08-03
-$18.05M
10-Q · filed 2018-08-03
-$57.29M
derived: sum of 3 quarters · filed 2018-08-03
-$67.49M
derived: sum of 4 quarters · filed 2018-08-03
2017-03-31-$10.00M
10-Q · filed 2018-05-08
-$49.24M
derived: sum of 2 quarters · filed 2018-05-08
-$59.44M
derived: sum of 3 quarters · filed 2018-05-08
-$69.64M
derived: sum of 4 quarters · filed 2018-05-08
2016-12-31-$39.24M
10-K · filed 2017-03-15
-$49.44M
derived: sum of 2 quarters · filed 2017-11-09
-$59.64M
derived: sum of 3 quarters · filed 2017-11-09
-$39.24M
10-K · filed 2018-02-26
2016-09-30-$10.20M
10-Q · filed 2017-11-09
-$20.40M
derived: sum of 2 quarters · filed 2017-11-09
-$30.66M
10-Q · filed 2017-11-09
-$58.16M
derived: sum of 4 quarters · filed 2017-11-09
2016-06-30-$10.20M
10-Q · filed 2017-08-09
-$10.20M
10-Q · filed 2016-08-04
-$20.46M
10-Q · filed 2017-08-09
-$20.47M
10-Q · filed 2016-08-04
-$47.96M
derived: sum of 3 quarters · filed 2017-08-09
-$50.69M
derived: sum of 4 quarters · filed 2017-08-09
2016-03-31-$10.26M
10-Q · filed 2017-05-10
-$10.27M
10-Q · filed 2016-05-10
-$37.76M
derived: sum of 2 quarters · filed 2017-05-10
-$40.49M
derived: sum of 3 quarters · filed 2017-05-10
-$50.68M
derived: sum of 4 quarters · filed 2017-05-10
2015-12-31-$27.50M
10-K · filed 2017-03-15
-$30.23M
derived: sum of 2 quarters · filed 2017-03-15
-$40.42M
derived: sum of 3 quarters · filed 2017-03-15
-$47.60M
derived: sum of 4 quarters · filed 2017-03-15
2015-09-30-$2.74M
10-Q · filed 2016-11-09
-$12.92M
derived: sum of 2 quarters · filed 2016-11-09
-$20.09M
10-Q · filed 2016-11-09
2015-06-30-$10.19M
10-Q · filed 2016-08-04
-$17.37M
10-Q · filed 2016-08-04
2015-03-31-$7.18M
10-Q · filed 2016-05-10
2014-12-31-$14.35M
10-K · filed 2017-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
COGNITION THERAPEUTICS INC (CGTX)United States$0.090B-6.52
Pelthos Therapeutics Inc. (PTHS)United States$0.086B-1.20
Atara Biotherapeutics, Inc. (ATRA)United States$0.086B-6.48
LENZ Therapeutics, Inc. (LENZ)United States$0.117B-1.41
Vaxart, Inc. (VXRT)United States$0.080B3.84
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Kalaris Therapeutics, Inc. (KLRS)United States$0.073B-2.19
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B